Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 4
1993 2
1994 3
1995 3
1996 4
1997 1
1998 2
1999 4
2000 1
2001 2
2002 6
2003 5
2004 2
2005 8
2006 8
2007 3
2008 9
2009 15
2010 13
2011 22
2012 16
2013 6
2014 14
2015 15
2016 17
2017 9
2018 9
2019 5
2020 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Results by year
Filters applied: . Clear all
Page 1
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Grønberg BH, et al. Among authors: bremnes rm. J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433683 Clinical Trial.
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Among authors: bremnes rm. J Clin Oncol. 2002 Dec 15;20(24):4665-72. doi: 10.1200/JCO.2002.12.111. J Clin Oncol. 2002. PMID: 12488411 Clinical Trial.
192 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page